NewsMeter
The direct-to-consumer prescription pathway for GLP-1 weight-loss drugs is set to redirect pharmacy volume toward a concentrated group of retail chains.
Walmart, Costco and Amazon are the three named beneficiaries as Americans are encouraged to go direct for weight-loss drug prescriptions.
The sourced analysis frames this as a win for retail pharmacy chains without attaching a number to how large that win will be. The mechanics of the direct model The argument turns on prescription fill behavior.
When patients obtain prescriptions directly, they choose their own fill point. Walmart, Costco and Amazon are the retailers the analysis identifies as best positioned to absorb that demand.
Keep reading